The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review.

[1]  E. Goldsmith,et al.  Structural basis of latency in plasminogen activator inhibitor-1 , 1992, Nature.

[2]  P. Stein,et al.  Mobile reactive centre of serpins and the control of thrombosis , 1991, Nature.

[3]  S. Seely.  The Caerphilly study. , 1991, International journal of cardiology.

[4]  C. Reilly,et al.  Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[5]  S. Humphries,et al.  Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers , 1991, Thrombosis and Haemostasis.

[6]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  C. Hack,et al.  PAI-1 Synthesis in the Human Hepatoma Cell Line Hep G2 Is Increased by Cytokines - Evidence that the Liver Contributes to Acute Phase Behaviour of PAI-1 , 1991, Thrombosis and Haemostasis.

[8]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[9]  B. Bennett,et al.  Distribution of plasminogen activator inhibitor (PAI-1) in tissues. , 1991, Journal of clinical pathology.

[10]  J. Billadello,et al.  Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. , 1991, The Journal of biological chemistry.

[11]  S. Dawson.  Genetic variation at the plasminogen activator inhibitor-1 locus and its effect on plasminogen activator inhibitor-1 expression. , 1991 .

[12]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[13]  B. Sobel,et al.  Induction of Synthesis of Plasminogen Activator Inhibitor Type-1 byTissue-Type Plasminogen Activator in Human Hepatic and Endothelial Cells , 1990, Thrombosis and Haemostasis.

[14]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[15]  D. Rifkin,et al.  Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.

[16]  K. Marotti,et al.  Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene , 1990, Nature.

[17]  A. Hamsten,et al.  The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease , 1990, Seminars in thrombosis and hemostasis.

[18]  U. Smith,et al.  The influence of metformin on the fibrinolytic system and insulin resistance in patients with hypertension , 1990 .

[19]  E. Tremoli,et al.  Atherogenic lipoproteins and release of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells , 1990 .

[20]  C. Forbes,et al.  Seasonal variation in fibrinolysis in patients with rheumatoid arthritis , 1990 .

[21]  A. Cohen,et al.  Life style and blood fibrinolytic activity: a comment on clearance of plasminogen activators , 1990 .

[22]  D. Keber,et al.  Shift work and circadian rhythm of blood fibrinolytic parameters , 1990 .

[23]  D. Keber,et al.  Plasminogen activator inhibitor I response to a carbohydrate meal in obese subjects , 1990 .

[24]  T. Lindahl,et al.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. , 1990, The Biochemical journal.

[25]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[26]  K. Preissner,et al.  Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. , 1989, Blood.

[27]  P. Bosma,et al.  Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes , 1989, Thrombosis and Haemostasis.

[28]  James Scott.  Thrombogenesis linked to atherogenesis at last? , 1989, Nature.

[29]  D. Dichek,et al.  Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. , 1989, Blood.

[30]  J. Schellekens,et al.  Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock , 1989, Thrombosis and Haemostasis.

[31]  E. Goldsmith,et al.  Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.

[32]  J. Parrillo,et al.  Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. , 1989, The New England journal of medicine.

[33]  M. Alessi,et al.  Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response , 1989, Arteriosclerosis.

[34]  B. Eriksson,et al.  Thrombosis after hip replacement. Relationship to the fibrinolytic system. , 1989, Acta orthopaedica Scandinavica.

[35]  W. Chandler,et al.  Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). , 1989, Circulation.

[36]  F. Lithner,et al.  Glycaemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type I diabetic patients but microangiopathy does not. , 2009, Acta medica Scandinavica.

[37]  T. Kooistra,et al.  Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 , 1988, Thrombosis and Haemostasis.

[38]  K. Huber,et al.  Circadian Fluctuations of Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma of Patients with Unstable Coronary Artery Disease and Acute Myocardial Infarction , 1988, Thrombosis and Haemostasis.

[39]  O. Sigurdardottir,et al.  Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma , 1988, FEBS letters.

[40]  B. Sobel,et al.  Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. , 1988, The Journal of biological chemistry.

[41]  B. Bennett,et al.  Plasminogen activator inhibitor (PAI‐1) in plasma and platelets , 1988, British journal of haematology.

[42]  W. Fiers,et al.  TUMOR NECROSIS FACTOR INCREASES THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN ENDOTHELIAL CELLS IN VITRO AND IN RATS IN VIVO , 1988, Thrombosis and Haemostasis.

[43]  K. Preissner,et al.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). , 1988, The Journal of biological chemistry.

[44]  E. Koay,et al.  Altered Fibrinolysis in DVT: Influence of Site of Sampling , 1988, Thrombosis and Haemostasis.

[45]  S. Humphries,et al.  DNA polymorphisms of the apolipoprotein genes--their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. , 1988, Atherosclerosis.

[46]  P. Bosma,et al.  Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. , 1988, The Journal of biological chemistry.

[47]  H. Pannekoek,et al.  Mutants of human tissue-type plasminogen activator (t-PA): Structural aspects and functional properties , 1988 .

[48]  E. Kruithof,et al.  Diurnal Variation of the Fibrinolytic System , 1988, Thrombosis and Haemostasis.

[49]  F. España,et al.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. , 1988, British heart journal.

[50]  M. Gimbrone,et al.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. , 1988, The Journal of biological chemistry.

[51]  B. Wiman,et al.  Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. , 1988, The Biochemical journal.

[52]  L. Lund,et al.  The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene , 1988 .

[53]  J. Verheijen,et al.  Daytime Fluctuations in Blood of Tissue-Type Plasminogen Activator (t-PA) and Its Fast-Acting Inhibitor (PAI-1) , 1988, Thrombosis and Haemostasis.

[54]  S. Rahimtoola,et al.  Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.

[55]  A. Lusis.  Genetic factors affecting blood lipoproteins: the candidate gene approach. , 1988, Journal of lipid research.

[56]  J. Auwerx,et al.  Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.

[57]  M. Jaye,et al.  REGULATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 mRNA IN HUMAN ENDOTHELIAL CELLS , 1987, Thrombosis and Haemostasis.

[58]  K. Klinger,et al.  Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Sporn,et al.  Some recent advances in the chemistry and biology of transforming growth factor-beta , 1987, The Journal of cell biology.

[60]  D. Moscatelli,et al.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells , 1987, The Journal of cell biology.

[61]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[62]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[63]  S. Humphries,et al.  ROLE OF GENETIC VARIATION AT THE FIBRINOGEN LOCUS IN DETERMINATION OF PLASMA FIBRINOGEN CONCENTRATIONS , 1987, The Lancet.

[64]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[65]  T. Saldeen,et al.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. , 1987, Journal of the American College of Cardiology.

[66]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[67]  B. Wiman,et al.  Immunological Relationship Between Plasminogen Activator Inhibitors from Different Sources , 1987, Thrombosis and Haemostasis.

[68]  S. Willich,et al.  Circadian variation in the frequency of sudden cardiac death. , 1987, Circulation.

[69]  K. Berg.  DNA polymorphism at the apolipoprotein B locus is associated with lipoprotein level , 1986, Clinical genetics.

[70]  D. Lawrence,et al.  Inactivation of plasminogen activator inhibitor by oxidants. , 1986, Biochemistry.

[71]  H. Lambers,et al.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. , 1986, The EMBO journal.

[72]  T. Kooistra,et al.  Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells , 1986, The Journal of experimental medicine.

[73]  E. Kruithof,et al.  Studies on the Release of a Plasminogen Activator Inhibitor by Human Platelets , 1986, Thrombosis and Haemostasis.

[74]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.

[75]  M. Blombäck,et al.  Haemostatic function in myocardial infarction. , 1986, British heart journal.

[76]  T. Gelehrter,et al.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[77]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[78]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.

[79]  J. Paramo,et al.  Postoperative Changes in the Plasmatic Levels of Tissue-Type Plasminogen Activator and Its Fast-Acting Inhibitor - Relationship to Deep Vein Thrombosis and Influence of Prophylaxis , 1985, Thrombosis and Haemostasis.

[80]  D. Loskutoff,et al.  Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. , 1985, The Journal of biological chemistry.

[81]  F. Werf,et al.  Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.

[82]  L. Häggroth,et al.  Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. , 1985, Thrombosis research.

[83]  P. Elwood,et al.  Haemostatic factors and ischaemic heart disease. The Caerphilly study. , 1985, British heart journal.

[84]  H. Berger,et al.  Catabolism of human tissue plasminogen activator in mice. , 1985, Blood.

[85]  J. Paramo,et al.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. , 1985, The Journal of clinical investigation.

[86]  P. Wallén,et al.  In vivo metabolism of human tissue-type plasminogen activator. , 2009, Scandinavian journal of haematology.

[87]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[88]  T. Nilsson,et al.  Defective fibrinolysis in survivors of myocardial infarction. , 1984, International Journal of Cardiology.

[89]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[90]  B. Wiman,et al.  Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. , 1984, The Journal of biological chemistry.

[91]  B. Wiman,et al.  Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. , 1983, Thrombosis research.

[92]  P. Elwood,et al.  Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell study. , 1982, British heart journal.

[93]  A. Bloom.  Haemostasis and thrombosis , 1981 .

[94]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[95]  W. Kannel,et al.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. , 1979, Annals of internal medicine.

[96]  D. Loskutoff,et al.  Comparative studies of the fibrinolytic activity of cultured vascular cells. , 1979, Thrombosis research.

[97]  B. Wiman,et al.  Molecular mechanism of physiological fibrinolysis , 1978, Nature.

[98]  A. Nicolaides,et al.  BLOOD VISCOSITY, RED-CELL FLEXIBILITY, HÆMATOCRIT, AND PLASMA-FIBRINOGEN IN PATIENTS WITH ANGINA , 1977, The Lancet.

[99]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[100]  G. Reaven,et al.  Reappraisal of the role of insulin in hypertriglyceridemia. , 1974, The American journal of medicine.

[101]  I. Nilsson,et al.  Antithrombin III in a clinical material , 1973 .

[102]  W. Kannel,et al.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.

[103]  R. Chakrabarti,et al.  Blood Fibrinolytic Activity in Diabetes Mellitus and Its Bearing on Ischaemic Heart Disease and Obesity , 1963, British medical journal.

[104]  J. Ferguson,et al.  Arteriovenous difference in natural fibrinolysis. , 1957, Lancet.